Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935751 · ClinicalTrials.gov registry record
Apixaban Discontinuation Prior to Major Surgery
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 130
- Enrollment target
NCT02935751 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 130 participants.
The verdict
NCT02935751 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 130 participants
- Enrollment target
Study Summary
The ADIOS study is a prospective, observational study will evaluate one hundred and thirty (130) patients with non-valvular atrial fibrillation who are currently receiving treatment with apixaban as indicated to reduce the risk of stroke or systemic embolism, and who require an elective major surgical or invasive procedure will be included in the study. The purpose of the study is to evaluate the efficacy of the recommended pre-procedure washout period of 48 hours.
Interventions
- OTHER Lab tests for plasma levels of apixaban and anti-10a factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02935751
The ClinicalTrials.gov registry entry for NCT02935751 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lab tests for plasma levels of apixaban and anti-10a factor is the first listed.
NCT02935751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02935751 about?
NCT02935751 is a clinical study titled "Apixaban Discontinuation Prior to Major Surgery". The ADIOS study is a prospective, observational study will evaluate one hundred and thirty (130) patients with non-valvular atrial fibrillation who are currently receiving treatment with apixaban as indicated to reduce the risk of stroke or systemic embolism, and who require an elective major surgic...
What is the current status of trial NCT02935751?
This trial is currently completed. The enrollment target is 130 participants. The study started on 2016-10. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02935751?
The interventions under investigation include: Lab tests for plasma levels of apixaban and anti-10a factor (OTHER).
Who is sponsoring clinical trial NCT02935751?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.